Chronic Over-expression of Fibroblast Growth Factor 21 Increases Bile Acid Biosynthesis by Opposing FGF15/19 Action

EBioMedicine

Volumn 15, Issue , 2017, Pages 173-183

  Zhang, Jun ^a   Gupte, Jamila ^a   Gong, Yan ^a   Weiszmann, Jennifer ^a   Zhang, Yuan ^b   Lee, Ki Jeong ^a   Richards, William G ^a   Li, Yang ^a  

^a AMGEN INC   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Bile acid metabolism; FGF19; FGF21; FGFR4; Klotho

Indexed keywords

ABC TRANSPORTER G5; ABC TRANSPORTER G8; BILE SALT EXPORT PUMP; CHOLESTEROL; CHOLESTEROL 7ALPHA MONOOXYGENASE; FIBROBLAST GROWTH FACTOR 15; FIBROBLAST GROWTH FACTOR 19; FIBROBLAST GROWTH FACTOR 21; FIBROBLAST GROWTH FACTOR RECEPTOR 4; INSULIN; LIPOFECTAMINE; PARVOVIRUS VECTOR; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; BILE ACID; BIOLOGICAL MARKER; CYP7A1 PROTEIN, MOUSE; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 15, MOUSE; GLUCOSE; KLB PROTEIN, MOUSE; MEMBRANE PROTEIN; PROTEIN BINDING;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BILE ACID SYNTHESIS; BILE FLOW; BILE LEVEL; BODY WEIGHT; CB6F1 MOUSE; CHOLECYSTECTOMY; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DENSITY GRADIENT CENTRIFUGATION; DIET INDUCED OBESITY; DIET RESTRICTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FECES ANALYSIS; GENE CONTROL; GENE OVEREXPRESSION; GLUCOSE BLOOD LEVEL; LIPID HOMEOSTASIS; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ISOLATION; SKELETAL MYOBLAST; TRANSIENT TRANSFECTION; TRIACYLGLYCEROL BLOOD LEVEL; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; CELL LINE; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENETICS; HOMEOSTASIS; KNOCKOUT MOUSE; LIPID METABOLISM; METABOLISM; SIGNAL TRANSDUCTION;

ANIMALS; BILE ACIDS AND SALTS; BIOMARKERS; BODY WEIGHT; CELL LINE; CHOLESTEROL 7-ALPHA-HYDROXYLASE; FIBROBLAST GROWTH FACTORS; GENE EXPRESSION; GENE EXPRESSION REGULATION; GLUCOSE; HOMEOSTASIS; LIPID METABOLISM; MEMBRANE PROTEINS; MICE; MICE, KNOCKOUT; MODELS, ANIMAL; PROTEIN BINDING; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 4; SIGNAL TRANSDUCTION;

EID: 85009186291     PISSN: None     EISSN: 23523964     Source Type: Journal    
DOI: 10.1016/j.ebiom.2016.12.016     Document Type: Article

References (45)

1. Bennion, L.J., Grundy, S.M., Effects of diabetes mellitus on cholesterol metabolism in man. N. Engl. J. Med. 296 (1977), 1365–1371.
2. Coskun, T., Bina, H.A., Schneider, M.A., Dunbar, J.D., Hu, C.C., Chen, Y., Moller, D.E., Kharitonenkov, A., Fibroblast growth factor 21 corrects obesity in mice. Endocrinology 149 (2008), 6018–6027.
3. Ding, X., Boney-Montoya, J., Owen, B.M., Bookout, A.L., Coate, K.C., Mangelsdorf, D.J., Kliewer, S.A., betaKlotho is required for fibroblast growth factor 21 effects on growth and metabolism. Cell Metab. 16 (2012), 387–393.
4. Fu, L., John, L.M., Adams, S.H., Yu, X.X., Tomlinson, E., Renz, M., Williams, P.M., Soriano, R., Corpuz, R., Moffat, B., et al. Fibroblast growth factor 19 increases metabolic rate and reverses dietary and leptin-deficient diabetes. Endocrinology 145 (2004), 2594–2603.
5. Fu, T., Choi, S.E., Kim, D.H., Seok, S., Suino-Powell, K.M., Xu, H.E., Kemper, J.K., Aberrantly elevated microRNA-34a in obesity attenuates hepatic responses to FGF19 by targeting a membrane coreceptor beta-Klotho. Proc. Natl. Acad. Sci. U. S. A. 109 (2012), 16137–16142.
6. Gallego-Escuredo, J.M., Gomez-Ambrosi, J., Catalan, V., Domingo, P., Giralt, M., Fruhbeck, G., Villarroya, F., Opposite alterations in FGF21 and FGF19 levels and disturbed expression of the receptor machinery for endocrine FGFs in obese patients. Int. J. Obes. 39 (2015), 121–129.
7. Ge, H., Baribault, H., Vonderfecht, S., Lemon, B., Weiszmann, J., Gardner, J., Lee, K.J., Gupte, J., Mookherjee, P., Wang, M., et al. Characterization of a FGF19 variant with altered receptor specificity revealed a central role for FGFR1c in the regulation of glucose metabolism. PLoS One, 7, 2012, e33603.
8. Ge, H., Zhang, J., Gong, Y., Gupte, J., Ye, J., Weiszmann, J., Samayoa, K., Coberly, S., Gardner, J., Wang, H., et al. Fibroblast growth factor receptor 4 (FGFR4) deficiency improves insulin resistance and glucose metabolism under diet-induced obesity conditions. J. Biol. Chem. 289 (2014), 30470–30480.
9. Goetz, R., Ohnishi, M., Ding, X., Kurosu, H., Wang, L., Akiyoshi, J., Ma, J., Gai, W., Sidis, Y., Pitteloud, N., et al. Klotho coreceptors inhibit signaling by paracrine fibroblast growth factor 8 subfamily ligands. Mol. Cell. Biol. 32 (2012), 1944–1954.
10. Hao, Y., Zhou, J., Zhou, M., Ma, X., Lu, Z., Gao, M., Pan, X., Tang, J., Bao, Y., Jia, W., Serum levels of fibroblast growth factor 19 are inversely associated with coronary artery disease in Chinese individuals. PLoS One, 8, 2013, e72345.
11. Holt, J.A., Luo, G., Billin, A.N., Bisi, J., McNeill, Y.Y., Kozarsky, K.F., Donahee, M., Wang, D.Y., Mansfield, T.A., Kliewer, S.A., et al. Definition of a novel growth factor-dependent signal cascade for the suppression of bile acid biosynthesis. Genes Dev. 17 (2003), 1581–1591.
12. Hotta, Y., Nakamura, H., Konishi, M., Murata, Y., Takagi, H., Matsumura, S., Inoue, K., Fushiki, T., Itoh, N., Fibroblast growth factor 21 regulates lipolysis in white adipose tissue but is not required for ketogenesis and triglyceride clearance in liver. Endocrinology 150 (2009), 4625–4633.
13. Inagaki, T., Choi, M., Moschetta, A., Peng, L., Cummins, C.L., McDonald, J.G., Luo, G., Jones, S.A., Goodwin, B., Richardson, J.A., et al. Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. Cell Metab. 2 (2005), 217–225.
14. Ito, S., Fujimori, T., Furuya, A., Satoh, J., Nabeshima, Y., Nabeshima, Y., Impaired negative feedback suppression of bile acid synthesis in mice lacking betaKlotho. J. Clin. Invest. 115 (2005), 2202–2208.
15. Katafuchi, T., Esterhazy, D., Lemoff, A., Ding, X., Sondhi, V., Kliewer, S.A., Mirzaei, H., Mangelsdorf, D.J., Detection of FGF15 in plasma by stable isotope standards and capture by anti-peptide antibodies and targeted mass spectrometry. Cell Metab. 21 (2015), 898–904.
16. Kharitonenkov, A., Shiyanova, T.L., Koester, A., Ford, A.M., Micanovic, R., Galbreath, E.J., Sandusky, G.E., Hammond, L.J., Moyers, J.S., Owens, R.A., et al. FGF-21 as a novel metabolic regulator. J. Clin. Invest. 115 (2005), 1627–1635.
17. Kharitonenkov, A., Wroblewski, V.J., Koester, A., Chen, Y.F., Clutinger, C.K., Tigno, X.T., Hansen, B.C., Shanafelt, A.B., Etgen, G.J., The metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21. Endocrinology 148 (2007), 774–781.
18. Kong, B., Wang, L., Chiang, J.Y., Zhang, Y., Klaassen, C.D., Guo, G.L., Mechanism of tissue-specific farnesoid X receptor in suppressing the expression of genes in bile-acid synthesis in mice. Hepatology 56 (2012), 1034–1043.
19. Kurosu, H., Choi, M., Ogawa, Y., Dickson, A.S., Goetz, R., Eliseenkova, A.V., Mohammadi, M., Rosenblatt, K.P., Kliewer, S.A., Kuro-o, M., Tissue-specific expression of betaKlotho and fibroblast growth factor (FGF) receptor isoforms determines metabolic activity of FGF19 and FGF21. J. Biol. Chem. 282 (2007), 26687–26695.
20. Li, T., Owsley, E., Matozel, M., Hsu, P., Novak, C.M., Chiang, J.Y., Transgenic expression of cholesterol 7alpha-hydroxylase in the liver prevents high-fat diet-induced obesity and insulin resistance in mice. Hepatology 52 (2010), 678–690.
21. Li, T., Matozel, M., Boehme, S., Kong, B., Nilsson, L.M., Guo, G., Ellis, E., Chiang, J.Y., Overexpression of cholesterol 7alpha-hydroxylase promotes hepatic bile acid synthesis and secretion and maintains cholesterol homeostasis. Hepatology 53 (2011), 996–1006.
22. Li, X., Fan, X., Ren, F., Zhang, Y., Shen, C., Ren, G., Sun, J., Zhang, N., Wang, W., Ning, G., et al. Serum FGF21 levels are increased in newly diagnosed type 2 diabetes with nonalcoholic fatty liver disease and associated with hsCRP levels independently. Diabetes Res. Clin. Pract. 93 (2011), 10–16.
23. Li, T., Francl, J.M., Boehme, S., Ochoa, A., Zhang, Y., Klaassen, C.D., Erickson, S.K., Chiang, J.Y., Glucose and insulin induction of bile acid synthesis: mechanisms and implication in diabetes and obesity. J. Biol. Chem. 287 (2012), 1861–1873.
24. Lin, B.C., Wang, M., Blackmore, C., Desnoyers, L.R., Liver-specific activities of FGF19 require Klotho beta. J. Biol. Chem. 282 (2007), 27277–27284.
25. Lundasen, T., Galman, C., Angelin, B., Rudling, M., Circulating intestinal fibroblast growth factor 19 has a pronounced diurnal variation and modulates hepatic bile acid synthesis in man. J. Intern. Med. 260 (2006), 530–536.
26. Myant, N.B., Mitropoulos, K.A., Cholesterol 7 alpha-hydroxylase. J. Lipid Res. 18 (1977), 135–153.
27. Ogawa, Y., Kurosu, H., Yamamoto, M., Nandi, A., Rosenblatt, K.P., Goetz, R., Eliseenkova, A.V., Mohammadi, M., Kuro-o, M., BetaKlotho is required for metabolic activity of fibroblast growth factor 21. Proc. Natl. Acad. Sci. U. S. A. 104 (2007), 7432–7437.
28. Russell, D.W., Setchell, K.D., Bile acid biosynthesis. Biochemistry 31 (1992), 4737–4749.
29. Talukdar, S., Zhou, Y., Li, D., Rossulek, M., Dong, J., Somayaji, V., Weng, Y., Clark, R., Lanba, A., Owen, B.M., et al. A long-acting FGF21 molecule, PF-05231023, decreases body weight and improves lipid profile in non-human primates and type 2 diabetic subjects. Cell Metab. 23 (2016), 427–440.
30. Thomas, C., Pellicciari, R., Pruzanski, M., Auwerx, J., Schoonjans, K., Targeting bile-acid signalling for metabolic diseases. Nat. Rev. Drug Discov. 7 (2008), 678–693.
31. Tomlinson, E., Fu, L., John, L., Hultgren, B., Huang, X., Renz, M., Stephan, J.P., Tsai, S.P., Powell-Braxton, L., French, D., et al. Transgenic mice expressing human fibroblast growth factor-19 display increased metabolic rate and decreased adiposity. Endocrinology 143 (2002), 1741–1747.
32. Walters, J.R., Bile acid diarrhoea and FGF19: new views on diagnosis, pathogenesis and therapy. Nat. Rev. Gastroenterol. Hepatol. 11 (2014), 426–434.
33. Wu, X., Li, Y., Therapeutic utilities of fibroblast growth factor 19. Expert Opin. Ther. Targets 15 (2011), 1307–1316.
34. Wu, X., Ge, H., Gupte, J., Weiszmann, J., Shimamoto, G., Stevens, J., Hawkins, N., Lemon, B., Shen, W., Xu, J., et al. Co-receptor requirements for fibroblast growth factor-19 signaling. J. Biol. Chem. 282 (2007), 29069–29072.
35. Wu, X., Lemon, B., Li, X., Gupte, J., Weiszmann, J., Stevens, J., Hawkins, N., Shen, W., Lindberg, R., Chen, J.L., et al. C-terminal tail of FGF19 determines its specificity toward Klotho co-receptors. J. Biol. Chem. 283 (2008), 33304–33309.
36. Wu, X., Ge, H., Lemon, B., Weiszmann, J., Gupte, J., Hawkins, N., Li, X., Tang, J., Lindberg, R., Li, Y., Selective activation of FGFR4 by an FGF19 variant does not improve glucose metabolism in Ob/Ob mice. Proc. Natl. Acad. Sci. U. S. A. 106 (2009), 14379–14384.
37. Wu, X., Ge, H., Lemon, B., Vonderfecht, S., Weiszmann, J., Hecht, R., Gupte, J., Hager, T., Wang, Z., Lindberg, R., et al. FGF19-induced hepatocyte proliferation is mediated through FGFR4 activation. J. Biol. Chem. 285 (2010), 5165–5170.
38. Wu, A.L., Coulter, S., Liddle, C., Wong, A., Eastham-Anderson, J., French, D.M., Peterson, A.S., Sonoda, J., FGF19 regulates cell proliferation, glucose and bile acid metabolism via FGFR4-dependent and independent pathways. PLoS One, 6, 2011, e17868.
39. Xu, J., Lloyd, D.J., Hale, C., Stanislaus, S., Chen, M., Sivits, G., Vonderfecht, S., Hecht, R., Li, Y.S., Lindberg, R.A., et al. Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice. Diabetes 58 (2009), 250–259.
40. Xu, J., Stanislaus, S., Chinookoswong, N., Lau, Y.Y., Hager, T., Patel, J., Ge, H., Weiszmann, J., Lu, S.C., Graham, M., et al. Acute glucose-lowering and insulin-sensitizing action of FGF21 in insulin-resistant mouse models–association with liver and adipose tissue effects. Am. J. Physiol. Endocrinol. Metab. 297 (2009), E1105–E1114.
41. Yang, C., Jin, C., Li, X., Wang, F., McKeehan, W.L., Luo, Y., Differential specificity of endocrine FGF19 and FGF21 to FGFR1 and FGFR4 in complex with KLB. PLoS One, 7, 2012, e33870.
42. Yu, C., Wang, F., Kan, M., Jin, C., Jones, R.B., Weinstein, M., Deng, C.X., McKeehan, W.L., Elevated cholesterol metabolism and bile acid synthesis in mice lacking membrane tyrosine kinase receptor FGFR4. J. Biol. Chem. 275 (2000), 15482–15489.
43. Yu, H., Xia, F., Lam, K.S., Wang, Y., Bao, Y., Zhang, J., Gu, Y., Zhou, P., Lu, J., Jia, W., et al. Circadian rhythm of circulating fibroblast growth factor 21 is related to diurnal changes in fatty acids in humans. Clin. Chem. 57 (2011), 691–700.
44. Zhang, J., Li, Y., Fibroblast growth factor 21, the endocrine FGF pathway and novel treatments for metabolic syndrome. Drug Discov. Today 19 (2014), 579–589.
45. Zhang, X., Yeung, D.C., Karpisek, M., Stejskal, D., Zhou, Z.G., Liu, F., Wong, R.L., Chow, W.S., Tso, A.W., Lam, K.S., et al. Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans. Diabetes 57 (2008), 1246–1253.